Skip to main content
  • Log in

Dundee Research Interest Group

Dealing with Parkinson's Research

Main navigation

  • Home
  • About
    • About Us
    • DRIG Business
    • Glossary
  • News
  • Events
    • Upcoming Events
    • Past Events
    • Lab Visit Reports
  • Patients
    • My Parkinson's
    • Parky Poetry
  • Research
    • Research In Depth
    • Trials
  • Contact

Main navigation

  • Home
  • About
    • About Us
    • DRIG Business
    • Glossary
  • News
  • Events
    • Upcoming Events
    • Past Events
    • Lab Visit Reports
  • Patients
    • My Parkinson's
    • Parky Poetry
  • Research
    • Research In Depth
    • Trials
  • Contact

Resource | LRRK2 in Parkinson’s

Spring 2018 Conference

Prof Dario Alessi

My laboratory is focused on deciphering the molecular causes of Parkinson’s. We believe that if we can comprehend what causes Parkinson’s, this will enable Researchers, Clinicians and Pharmaceutical Companies to work together to develop better ways to diagnose and treat the condition in the future. The approach we are taking is to study how mutations in certain genes cause Parkinson’s. One of the genes that we are working most on is called “LRRK2”. The LRRK2 gene is one of the most commonly mutated genes that causes familial inherited Parkinson’s. The LRRK2 gene encodes for a protein that is called the “LRRK2 enzyme”. Important research by our laboratory and others has shown that Parkinson’s mutations activate the LRRK2 enzyme.

This has led to the suggestions that drugs that target the LRRK2 enzyme could be developed for the better treatment of Parkinson’s. Excitingly, a company called Denali, based in San Francisco has recently launched the first clinical trials to test this idea. Several other companies are expected to initiate LRRK2 Parkinson’s trials soon.

These new drugs have the potential to slow down the progression of Parkinson’s.  

I will talk about the highlights of our recent research that have led to the discovery of how the LRRK2 enzyme works to control the activity of another set of enzymes called Rab.  I will describe recent work that has resulted in the discovery that mutation in several other genes that cause Parkinson’s, are also excitingly linked to the LRRK2 and Rab enzymes. Our work is revealing that LRRK2 is at the centre of a physiological network which is critical to understanding Parkinson’s. I will explain that with this increasing knowledge of the genetics and biology underlining Parkinson’s, I feel optimistic.

I believe that it is not unrealistic that with continued and expanded research efforts, major strides towards better treating Parkinson’s disease can be made in the coming years. Patient’s support and involvement in research is vital for success!

Resource File
Dario's Presentation

Helpline

0808 800 0303

The Parkinson’s UK helpline is a free and confidential service providing support to anyone affected by Parkinson’s.

hello@parkinsons.org.uk
Emails answered within 5 working days.

Text relay: 18001 0808 800 0303
Textphone number for textphone users only.

Support for you

  • Worried you have Parkinson's?
  • Carer or family member?
  • Find local support
  • Health or social care professionals
  • Living with Parkinson's
  • Recently diagnosed?

Follow us

  • Facebook
  • Twitter
  • YouTube
  • Instagram
  • Email

Parkinson's UK

Parkinson's UK
215 Vauxhall Bridge Road
London
SW1V 1EJ

Tel: 020 7931 8080

Parkinson's UK is the operating name of the Parkinson's Disease Society of the United Kingdom. 

A registered charity in England and Wales (258197) and in Scotland (SC037554).

Privacy Policy
Web Design by Matthew Elliott
2020 © Dundee Research Interest Group